Primary Pulmonary Hypertension
AttorneyOne.com is a free nationwide legal referral service. We are not a law firm. We help consumers find the best representation for their legal needs.
If you or a loved one are in need of legal assistance concerning Primary Pulmonary Hypertension you should get a lawyer on your side immediately. You will pay no attorney fees unless you win your case.
Email up to 10 Primary Pulmonary Hypertension law firms in one click; by filling out the simple Free Case Evaluation form.
For additional info on Primary Pulmonary Hypertension use the related topic links on the far right.
Primary Pulmonary Hypertension In The News
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival in Advanced Breast CancerGenentech, Inc. (NYSE:DNA) today announced that a Phase III study (RIBBON 1) of Avastin ® (bevacizumab), in combination with taxane, anthracycline-based or capecitabine chemotherapies for first-line treatment of metastatic HER2-negative breast cancer, met its primary endpoint of increasing the time patients lived without their disease advancing, compared to the chemotherapies alone. The primary .
Pulmonary Hypertension Treated with Stem CellsDr. Leonel Fernandez Liriano, Professor of Medicine at Pontifical Catholic University School of Medicine (PCUSM), announced nine month follow up results for the first patient treated with engineered stem cells in a clinical study of primary pulmonary hypertension. The stem cells are extracted from patients’ own blood and trained to become new blood vessels.
Woman wants to raise awareness of pulmonary hypertensionDiane Ramirez was 24 years old when she was diagnosed with pulmonary hypertension - a disease that is rare, incurable and life threatening if left untreated.
Aunt's illness drives boy to collect penniesA little boy is doing everything he can to help his aunt fight lung disease. Even if he does it one penny at a time. Six-year-old Ethan Campbell last year collected dimes for diabetes at his elementary school, then turned to his mother and asked who else he could help.
Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure ResultsNicOx S.A. today announced that the third pivotal phase 3 study for naproxcinod in patients with OA of the hip showed a highly statistically significant result on all three co-primary efficacy endpoints of the trial.
International Medical Team Announces Patient Results In Adult Stem Cell Clinical Study For Pulmonary HypertensionDr. Leonel Fernandez Liriano, Professor of Medicine at Pontifical Catholic University School of Medicine (PCUSM), announced nine month follow up results for the first patient treated with engineered stem cells in a clinical study of primary pulmonary hypertension. The stem cells are extracted from patients' own blood and trained to become new blood vessels. Zannos Grekos, M.D.
Third pivotal phase 3 study for NicOx' naproxcinod shows positive efficacy, safety and blood pressure resultsFirst CINOD meets all three co- primary endpoints in the 303 hip osteoarthritis study and shows no detrimental effect on blood pressure
Follow up results from first case of pulmonary hypertension treated with stem cellsDr. Leonel Fernandez Liriano, Professor of Medicine at Pontifical Catholic University School of Medicine (PCUSM), announced nine month follow up results for the first patient treated with engineered stem cells in a clinical study of primary pulmonary hypertension.
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast CancerGenentech, Inc. (NYSE:DNA) today announced that a Phase III study (RIBBON 1) of Avastin® (bevacizumab), in combination with taxane, anthracycline-based or capecitabine chemotherapies for first-line treatment of metastatic HER2-negative breast cancer, met its primary endpoint of increasing the time patients lived without their disease advancing, compared to the chemotherapies alone.
Third Pivotal Phase 3 Study For NicOx' Naproxcinod Shows Positive Efficacy, Safety And Blood Pressure ResultsNicOx S.A. (NYSE Euronext Paris: COX) announced that the third pivotal phase 3 study for naproxcinod in patients with OA of the hip showed a highly statistically significant result (pResults clearly support naproxcinod's non-detrimental blood pressure profile The blood pressure data for naproxcinod 750 mg bid were consistent with those obtained in the 301 and 302 studies.
